PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.59%
Both companies show declining cash positions (-7.59% vs AXSM's -7.29%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Similar yoy growth to AXSM's -7.29%. Walter Schloss would note comparable liquidity expansions. Examine capital usage strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of AXSM's 19.36%. David Dodd sees a leaner approach to short-term items.
-8.57%
≥ 1.5x AXSM's -1.47%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-5.56%
Similar yoy growth to AXSM's -5.24%. Walter Schloss sees parallel capital spending strategies. Check utilization rates.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.97%
Higher Long-Term Investments Growth compared to AXSM's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
0.75-0.9x AXSM's -5.75%. Bill Ackman questions if the competitor invests more robustly in future growth.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
≥ 1.5x AXSM's -2.10%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-2.42%
Less than half of AXSM's 39.80%. David Dodd sees a more disciplined AP approach or lower volume.
3.64%
Less than half of AXSM's 189.27%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-101.55%
Similar yoy growth to AXSM's -100.00%. Walter Schloss notes parallel approach to deferred revenue.
-3.64%
Less than half of AXSM's 262.87%. David Dodd sees fewer expansions in other current obligations.
-2.05%
Less than half of AXSM's 21.10%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.51%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.32%
Less than half of AXSM's 19.25%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-0.65%
Less than half of AXSM's 19.89%. David Dodd sees far fewer liability expansions relative to competitor.
3.70%
Higher Common Stock (Book Value) Growth compared to AXSM's zero value, indicating worse performance.
-2.84%
Below half AXSM's -13.39%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.53%
0.5-0.75x AXSM's -29.14%. Martin Whitman is wary of lagging equity growth vs. competitor.
-8.43%
≥ 1.5x AXSM's -2.10%. David Dodd sees faster overall balance sheet growth than competitor.
0.97%
Higher Total Investments Growth compared to AXSM's zero value, indicating better performance.
-4.43%
Less than half of AXSM's 0.43%. David Dodd sees less overall debt expansion vs. competitor.
7.68%
50-75% of AXSM's 13.49%. Bruce Berkowitz notes comparatively lower net debt expansion.